Moreover, the platelet‐derived growth factor receptor (PDGFR) inhibitors sunitinib and ponatinib significantly suppress the proliferation and metastasis of triple‐negative breast cancer cell lines.[9] In malignant melanoma, PDGFC dimers promote tumor growth in a paracrine manner by recruiting and activating cancer‐associated fibroblasts (CAFs).[10] These studies have indicated that PDGFC may be involved in the malignant progression of various tumors, but the specific cancer‐promoting mechanisms are quite different. This evidence concerns the gene PDGFRB and neoplasm.